Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
AroCell AB
AROCAroCell AB (publ), a vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers. The company provides AroCell TK 210 ELISA, an immunoassay kit for the determination of human Thymidine Kinase 1 protein concentration in blood samples; and UBC Rapid for diagnosing and monitoring bladder cancer patients. It also offers TUBEX TF, an in vitro diagnostic test for the detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden. Address: KarlsbodavAegen 39, Stockholm, Sweden, 168 67
Analytics
Precio Objetivo de WallStreet
10.07 SEKRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave AROC
Análisis de dividendos AROC
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout AROC
Valoración de la acción AROC
Finanzas AROC
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |